523 results on '"Gensler, Lianne S."'
Search Results
102. Additional file 1 of Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
103. sj-docx-2-tab-10.1177_1759720X211057975 ��� Supplemental material for Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
104. Additional file 1 of Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
105. The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administrationʼs Comments and Concerns
106. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study
107. Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis
108. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
109. 44092 Tuberculid reactions at a US academic medical center: A retrospective review
110. 44261 Cutaneous tuberculosis at a US academic medical center: A retrospective review
111. Identifying trajectories of radiographic spinal disease in ankylosing spondylitis: a 15-year follow-up study of the PSOAS cohort.
112. Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients.
113. Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
114. Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
115. AxSpA_review_Baraliakos_Appendix_TherAdvMuscDis_23Dec19 – Supplemental material for Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review
116. Ixekizumab Improves Functioning and Health in the Treatment of Active Non-Radiographic Axial Spondyloarthritis: 52-Week Results, COAST-X Trial
117. Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
118. Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time
119. Contributors
120. The Association of Tumor Necrosis Factor Inhibitor Use With Incident Hypertension in Ankylosing Spondylitis: Data From the PSOAS Cohort.
121. 121 - Clinical features of axial spondyloarthritis
122. Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies
123. Cardiovascular Risk Scores in Axial Spondyloarthritis Versus the General Population: A Cross-sectional Study
124. Examining Treatment Decision‐Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey
125. Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis
126. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
127. EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies
128. Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials
129. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
130. Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review
131. A latent class based imputation method under Bayesian quantile regression framework using asymmetric Laplace distribution for longitudinal medication usage data with intermittent missing values
132. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
133. Assessing Physical Activity and Sleep in Axial Spondyloarthritis: Measuring the Gap
134. A single center evaluation of applicant experiences in virtual interviews across eight internal medicine subspecialty fellowship programs.
135. Colaboradores
136. Repeated Spinal Mobility Measures and Their Association With Radiographic Damage in Ankylosing Spondylitis.
137. Multimorbidity phenotypes in ankylosing spondylitis and their association with disease activity and functional impairment: Data from the prospective study of outcomes in ankylosing spondylitis cohort.
138. A Terminal Event
139. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
140. Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts
141. FRI0397 EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS TREATED WITH CERTOLIZUMAB PEGOL: RESULTS FROM THE 48-WEEK RUN-IN PART OF C-OPTIMISE
142. AB0711 IXEKIZUMAB IMPROVES SIGNS AND SYMPTOMS AND SPINAL INFLAMMATION OF ANKYLOSING SPONDYLITIS/RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS THROUGH ONE YEAR OF TREATMENT IN BIOLOGIC DISEASE MODIFYING ANTI-RHEUMATIC DRUG-NAÏVE PATIENTS
143. THU0385 COMPARISON OF CLINICAL AND DEMOGRAPHIC FEATURES OF JUVENILE SPONDYLOARTHRITIS BETWEEN ISRAELI AND US CHILDREN
144. OP0231 DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB WAS ASSOCIATED WITH IMPROVEMENTS IN PATIENT-REPORTED AND QUALITY-OF-LIFE OUTCOMES IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
145. FRI0398 IXEKIZUMAB IS EFFECTIVE IN THE TREATMENT OF RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS REGARDLESS OF THE LEVEL OF C-REACTIVE PROTEIN OR MAGNETIC RESONANCE IMAGING SCORES: 16-WEEK DATA FROM COAST-V AND COAST-W
146. FRI0408 EARLIER TREATMENT OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH CERTOLIZUMAB PEGOL RESULTS IN IMPROVED CLINICAL OUTCOMES
147. FRI0380 SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENT OF ENTHESITIS IN PATIENTS WITH ANKYLOSING SPONDYLITIS: POOLED ANALYSIS OF FOUR PIVOTAL PHASE 3 STUDIES
148. OP0031 ARE THE MODIFIED NEW YORK AND ASAS AXIAL SPONDYLOARTHRITIS CRITERIA INTERCHANGEABLE IN THE CLASSIFICATION OF SPONDYLOARTHRITIS PATIENTS WITH RADIOGRAPHIC SACROILIITIS: COMPARISON IN 8 COHORTS?
149. AB1321 PSYCHOMETRIC PROPERTIES OF THE ASAS HEALTH INDEX IN PATIENTS WITH ACTIVE AS/RADIOGRAPHIC AXIAL SPA WHO HAVE PRIOR INADEQUATE RESPONSE/INTOLERANCE TO TNF INHIBITORS IN A PHASE 3 TRIAL
150. A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.